On this page
DIS3L2
DIS3 like 3'-5' exoribonuclease 2
DIS3L2 encodes a ribonuclease enzyme that degrades specific RNA molecules, and pathogenic variants cause Perlman syndrome, a rare overgrowth disorder with increased cancer risk. The DIS3L2 gene provides instructions for making an exoribonuclease enzyme that breaks down certain RNA molecules in the cell.
DIS3L2 is located on the long (q) arm of chromosome 2, at band 2q37.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 2 in the library →Available at Jeen Health
Clinical tests that include this
Overview
DIS3L2 is located on chromosome 2 and encodes DIS3 like 3'-5' exoribonuclease 2, an enzyme responsible for degrading specific RNA substrates within the cell. This protein belongs to the RNase II family of 3' to 5' exoribonucleases, which play crucial roles in controlling the abundance and stability of various RNA species. The gene's name reflects its structural similarity to the DIS3 enzyme, though DIS3L2 has distinct substrate preferences and cellular functions.
Pathogenic variants in DIS3L2 follow an autosomal recessive inheritance pattern, meaning that affected individuals carry changes in both gene copies. Loss of functional DIS3L2 protein disrupts normal RNA turnover pathways, leading to accumulation of specific RNA targets. This molecular disruption manifests clinically as Perlman syndrome, a rare congenital disorder affecting multiple organ systems. The condition presents with overgrowth before and after birth, characteristic dysmorphic features, intellectual disability, and a markedly increased susceptibility to Wilms tumour, a type of kidney cancer that typically develops in early childhood.
DIS3L2 is classified as an ACMG Secondary Findings gene (version 3.2), reflecting its clinical significance in cancer predisposition. Identification of biallelic pathogenic variants has important implications for cancer surveillance protocols, particularly for Wilms tumour screening during the first years of life.
What the gene does
The DIS3L2 protein functions as a 3' to 5' exoribonuclease, meaning it degrades RNA molecules by sequentially removing nucleotides from the 3' end of the strand. This enzymatic activity is essential for controlling the levels of specific RNA substrates in the cytoplasm. The protein shows particular selectivity for RNAs that have been modified with a polyuridine tail, a molecular tag that marks certain transcripts for degradation. By recognising and processing these tagged RNAs, DIS3L2 serves as a critical quality control mechanism in cellular RNA metabolism.
One of the most important substrates for DIS3L2 is a group of microRNAs derived from the mitochondrial genome. MicroRNAs are small regulatory molecules that can influence the expression of other genes by binding to messenger RNAs and either blocking their translation or promoting their degradation. Research suggests that DIS3L2 degrades specific mitochondrial microRNAs that would otherwise accumulate to harmful levels. When DIS3L2 is absent or non-functional, these regulatory RNAs persist in the cell and can inappropriately suppress genes that normally control cell growth and proliferation.
The protein also participates in broader RNA surveillance pathways that monitor and eliminate aberrant transcripts. Cells continuously produce improperly processed or damaged RNA molecules as byproducts of transcription errors, and efficient clearance of these molecules is necessary for maintaining normal cellular function. DIS3L2 works in concert with other RNA-processing enzymes and RNA-binding proteins to identify and degrade problematic transcripts before they can interfere with essential processes.
Evidence suggests that DIS3L2 activity is particularly important during embryonic development and early growth. The enzyme helps establish proper patterns of gene expression during organogenesis, and its absence leads to dysregulated growth signalling in multiple tissues. The overgrowth phenotype seen in Perlman syndrome likely reflects cumulative effects of impaired RNA quality control across many cell types during critical developmental windows. Additionally, loss of DIS3L2-mediated degradation of specific microRNAs may directly promote excessive cell division by removing normal brakes on proliferation pathways, contributing both to generalised overgrowth and to increased cancer susceptibility.
Video: Genetics 101
Chromosome location
DIS3L2 is located on the long arm of chromosome 2 at position 37.1, designated as 2q37.1. This chromosomal region lies near the telomere of chromosome 2, in a band associated with several other developmental disorder genes. The gene spans a substantial genomic interval and contains multiple exons that are transcribed and spliced together to produce the mature messenger RNA template for protein synthesis.
The 2q37 region has been recognised as a critical interval for normal development, and deletions or rearrangements affecting this area can lead to a spectrum of clinical features including growth abnormalities, developmental delay, and skeletal anomalies. While DIS3L2 is one gene within this region, its specific contribution to the phenotype becomes apparent when both copies carry pathogenic variants, as occurs in Perlman syndrome. The genomic neighbourhood surrounding DIS3L2 contains regulatory elements that may influence the gene's expression during development, though the specific transcriptional control mechanisms remain an active area of investigation.
Protein structure
The DIS3L2 protein is composed of 885 amino acids and contains structural features characteristic of the RNase II family of exoribonucleases. Disordered regions are present at both the N-terminus (protein start, amino acids 1-45) and the C-terminus (protein end, amino acids 860-885). These disordered segments lack stable three-dimensional structure and typically serve regulatory or protein-interaction functions rather than direct catalytic roles.
The core catalytic machinery of DIS3L2 resides in a central domain that adopts a characteristic fold enabling 3' to 5' exonuclease activity. This catalytic region contains the active site residues necessary for binding RNA substrates and cleaving phosphodiester bonds to release individual nucleotides. The enzyme's substrate specificity, particularly its preference for polyuridylated RNAs, is determined by structural features within and adjacent to the catalytic domain that create a binding pocket favouring uridine-rich sequences.
Additional structural elements within the protein contribute to RNA substrate recognition and processivity. The protein likely contains cold-shock domains or similar RNA-binding motifs that help position substrates correctly for degradation and maintain association with the RNA strand during successive cleavage events. The N-terminal disordered region may play a role in regulating enzyme activity or facilitating interactions with other components of RNA-processing complexes, though the precise functional contributions of the terminal disordered segments have not been fully characterised. Overall, the domain architecture reflects the protein's specialised role in recognising and degrading specific classes of tagged RNA molecules.
Key variants
Pathogenic variants in DIS3L2 that cause Perlman syndrome typically result in complete loss of functional protein from both gene copies. These include nonsense variants that introduce premature stop codons, frameshift variants caused by small insertions or deletions, and splice-site variants that disrupt normal messenger RNA processing. Larger deletions encompassing part or all of the gene have also been identified in affected individuals.
Because Perlman syndrome follows autosomal recessive inheritance, both parents of an affected child typically carry one pathogenic variant and one functional copy, making them unaffected carriers. Each pregnancy between two carrier parents has a 25% chance of producing a child with two pathogenic variants who will develop the condition, a 50% chance of producing a carrier child, and a 25% chance of producing a child with two functional copies.
Variant classification for DIS3L2 follows established guidelines that consider the type of genetic change, its predicted effect on protein function, population frequency data, and segregation patterns within families. Loss-of-function variants that clearly prevent production of functional enzyme are typically classified as pathogenic when identified in individuals with clinical features consistent with Perlman syndrome. Missense variants, which change a single amino acid, require more extensive evidence to determine pathogenicity, including functional studies, computational predictions, and correlation with clinical phenotype.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1096G>T | p.Glu366Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.1162C>T | p.Arg388Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.127C>T | p.Arg43Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.1810C>T | p.Gln604Ter | Pathogenic | ★★☆☆ | Perlman syndrome |
c.1983del | p.Thr662fs | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.2170C>T | p.Arg724Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.2219del | p.Asn740fs | Pathogenic | ★★☆☆ | Perlman syndrome |
c.2302del | p.Leu768fs | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.325dup | p.Asp109fs | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
c.48del | p.Arg17fs | Pathogenic/Likely pathogenic | ★★☆☆ | Perlman syndrome |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in DIS3L2 cause Perlman syndrome, a rare autosomal recessive disorder characterised by prenatal and postnatal overgrowth, distinctive craniofacial features, developmental delay, and predisposition to embryonal tumours, particularly Wilms tumour. Affected individuals typically present with macrosomia at birth, meaning a birth weight substantially above the normal range, along with visceromegaly (enlargement of internal organs including kidneys, liver, and pancreas).
The facial appearance in Perlman syndrome includes features such as a broad, prominent forehead, deep-set eyes, a broad nasal bridge, and an everted upper lip. Skeletal abnormalities may be present, and affected children generally show delayed motor and cognitive development. The most significant clinical concern is the markedly elevated risk of developing Wilms tumour during early childhood, with most Wilms tumours in Perlman syndrome diagnosed before five years of age. This cancer predisposition necessitates regular abdominal imaging surveillance in confirmed or suspected cases of Perlman syndrome to enable early detection and treatment of kidney tumours.
Inheritance pattern
Conditions caused by pathogenic DIS3L2 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
DIS3L2 appears on multiple NHS Genomic Medicine Service gene panels, reflecting its relevance across several clinical contexts. The gene holds green (high-evidence) classification status on the Beckwith-Wiedemann syndrome and other congenital overgrowth disorders panel, the Childhood solid tumours cancer susceptibility panel (R59), the Childhood solid tumours panel, DDG2P, the Fetal anomalies panel (R21), the Intellectual disability panel (R29), and the Skeletal dysplasia panel (R104).
Green classification indicates strong evidence supporting the gene-disease association, meaning that testing for DIS3L2 variants is considered clinically appropriate when Perlman syndrome or overlapping phenotypes are suspected. The inclusion on childhood cancer panels underscores the importance of genetic diagnosis for informing tumour surveillance protocols. Identification of biallelic pathogenic DIS3L2 variants enables implementation of structured Wilms tumour screening, typically involving regular renal ultrasound examinations during early childhood when risk is highest. Genetic diagnosis also facilitates cascade testing of family members to identify carrier relatives and inform reproductive planning.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals diagnosed with Perlman syndrome due to DIS3L2 variants, lifestyle management focuses primarily on medical surveillance rather than specific dietary or activity modifications. General principles of healthy childhood development apply, including balanced nutrition appropriate for growth needs, though affected children may require specialist input from dietitians familiar with overgrowth syndromes to ensure appropriate caloric intake without exacerbating excessive weight gain.
Physical activity recommendations should be individualised based on each child's developmental capabilities and any orthopaedic concerns. Some research suggests that maintaining appropriate physical activity levels during childhood supports overall health and development, though there is no evidence that specific exercise regimens influence tumour risk or syndrome severity in Perlman syndrome. Families should work with physiotherapists and developmental specialists to create appropriate activity plans that support motor skill development while accommodating any physical limitations.
The most critical lifestyle consideration involves adherence to recommended cancer surveillance schedules. Regular abdominal imaging, typically renal ultrasound performed every three months during early childhood, following protocols established by paediatric oncology guidelines, represents the cornerstone of clinical management. Evidence from other childhood cancer predisposition syndromes suggests that early tumour detection through systematic screening improves treatment outcomes and survival. Parents and caregivers should maintain consistent attendance at surveillance appointments and promptly report any new symptoms such as abdominal swelling, haematuria, or unexplained pain to healthcare providers.
Supplement considerations
There is no evidence that dietary supplements prevent Perlman syndrome, modify its clinical course, or reduce cancer risk in affected individuals. No specific vitamin, mineral, or nutritional product has demonstrated benefit in clinical studies or case reports for this condition. The fundamental cause - loss of functional DIS3L2 enzyme activity - cannot be addressed through nutritional supplementation.
Some families may consider general paediatric multivitamins or other supplements to support overall health and development. While standard age-appropriate vitamin supplementation following NHS guidance is generally considered safe, there is no basis for expecting such products to influence the underlying genetic condition or its complications. Before introducing any supplement, parents should discuss plans with their child's paediatrician or clinical geneticist to ensure there are no contraindications related to other aspects of the child's care.
Claims occasionally appear suggesting that antioxidant supplements or other products might reduce cancer risk in children with genetic predisposition syndromes. No credible evidence supports such claims for Perlman syndrome specifically, and families should be cautious about unproven interventions that might delay or substitute for evidence-based medical surveillance. The established approach to reducing cancer mortality in this condition remains regular imaging surveillance enabling early detection, combined with prompt specialist oncology care when tumours are identified.
Frequently asked questions
What is the difference between Perlman syndrome and Beckwith-Wiedemann syndrome?
Both conditions cause overgrowth and increased Wilms tumour risk, but they result from changes in different genes and have distinct features. Perlman syndrome, caused by DIS3L2 variants, typically presents with more severe developmental delay and characteristic facial features, while Beckwith-Wiedemann syndrome involves genes in the 11p15 region and often includes abdominal wall defects and macroglossia (enlarged tongue). Genetic testing can distinguish between them.
If I carry one DIS3L2 variant, will I develop health problems?
Carriers with one pathogenic variant and one functional gene copy do not develop Perlman syndrome and generally have no related health concerns. The condition requires pathogenic variants in both copies of the gene to manifest. Carriers may wish to discuss reproductive implications and partner testing with a genetic counsellor.
How often should children with Perlman syndrome have cancer screening?
Surveillance protocols typically recommend renal ultrasound every three months during early childhood when Wilms tumour risk is highest, often continuing until at least age five or as advised by the clinical team. The specific schedule should be determined by paediatric oncology and genetics specialists familiar with the child's individual circumstances.
Can prenatal testing identify DIS3L2 variants?
Yes, if pathogenic variants have been identified in family members, prenatal testing through chorionic villus sampling or amniocentesis can determine whether a pregnancy carries two pathogenic variants. Families considering prenatal testing should discuss options, implications, and limitations with a genetic counsellor before proceeding.
Why is DIS3L2 included on the ACMG Secondary Findings list?
DIS3L2 appears on the ACMG Secondary Findings list because identification of biallelic pathogenic variants has direct clinical utility - it enables implementation of Wilms tumour surveillance that can improve outcomes through early cancer detection. This actionable cancer predisposition justifies reporting incidental findings when performing genomic sequencing for other indications.
Are there treatments for Perlman syndrome beyond cancer screening?
Management is primarily supportive and includes developmental interventions such as physiotherapy, occupational therapy, and speech therapy tailored to each child's needs. Treatment of Wilms tumour, if it develops, typically involves surgery, chemotherapy, and sometimes radiotherapy, following established paediatric oncology protocols. Research into the molecular mechanisms of DIS3L2 deficiency continues, though targeted therapies are not currently available.